Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Bruno Bezerra Lima

Advanced Cardiac Imaging · VUMC

View

Dr. Sara Ersozlu

Advanced Cardiac Imaging · MGH

View

Dr. Christopher Kramer

Advanced Cardiac Imaging · University of Virginia

View

Dr. Filipe Moura

Advanced Cardiac Imaging · Yale College

View

Dr. Robert Hendel

Advanced Cardiac Imaging · Tulane University

View

Dr. Venkatesh Murthy

Advanced Cardiac Imaging · UMHS

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Phenotypic Spectrum of Subclinical Sarcomere-Related Hypertrophic Cardiomyopathy and Transition to Overt Disease.

    Jun 24, 2024DOI: 10.1161/circgen.124.004580Journal ArticleAHA

    Written by: Constantin-Cristian TopriceanuJames C MoonAnna Axelsson RajaGabriella CapturCarolyn Y Ho

    Find these authors on Roon

    CT
    Dr. Constantin-Cristian Topriceanu
    Advanced Cardiac Imaging · Mayo Clinic College of Medicine

    Introduction

    Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder that is frequently caused by pathogenic/ likely pathogenic (P/LP) variants in genes associated with the sarcomere apparatus. Genetic testing identifies a P/LP variant in 30–40% of adults with a clinical diagnosis of HCM, but >60% of patients diagnosed during childhood or with a family history of HCM have a P/LP1,2. The most commonly involved genes are myosin binding protein C (MYBPC3), β-myosin heavy chain (MYH7), troponin T (TNNT2) and troponin I (TNNI3) (Table 1). However, not all variant carriers (G+) demonstrate clinically overt HCM (LVH+) as the penetrance (the percentage [%] of G+ who have LVH in cross-sectional studies) and phenotypic conversion (% of G+ who develop LVH during short to medium term longitudinal follow-up) are variable; influenced by age, the specific gene, and clinical context amongst other currently unidentified genetic and environmental factors.Traditionally, HCM is diagnosed by the presence of unexplained LVH with maximal LV wall thickness (MWT) ≥15 mm (or ≥13mm for at-risk relatives or sarcomere variant carriers) on cardiac imaging-- echocardiography or cardiovascular MRI (CMR). Although LVH is a key feature, this binary definition of disease does not account for concurrent features that impact LV wall thickness, such as sex, ethnic background, comorbidities, or body size, leading to both under-diagnosis and over-diagnosis. The definition does not recognize that the disease is a continuum and that the absence of LVH cannot be translated to no phenotype in sarcomere variant carriers. A dichotomous cutoff also fails to encompass the complex phenotypic spectrum of HCM which extends beyond simple alteration of LV wall thickness. Furthermore, phenotypic manifestations of sarcomere variants are detectable prior to the emergence of LVH and fundamental to the pathophysiology of overt HCM. Abnormal cardiac morphology (e.g., small cavity size3), altered myocardial energetics (e.g., lower phosphocreatine-to-adenosine triphosphate [ATP] ratio on MR spectroscopy4), activation of pro-fibrotic pathways5,6, electrical abnormalities (e.g., pathological Q-waves on electrocardiogram [ECG]), diastolic dysfunction (e.g., lower global E’ velocities on Doppler echocardiography7), abnormal Ca2+ signaling, and microvascular dysfunction (e.g., perfusion defects on stress CMR8) have all been identified in subclinical HCM. Importantly, how these early phenotypic manifestations, individually or collectively, influences the evolution to overt HCM or prognosis is not well characterized. Moreover, the factors that render sarcomere variant carriers susceptible or resilient to developing penetrant disease are not understood. Given the absence of severe remodeling and extensive fibrosis, the subclinical stage could be more amenable to therapies aimed at attenuating disease progression or, ultimately, preventing disease emergence. However, reliable metrics of early phenotypic progression and inflection points where the natural course of the disease may be altered through intervention have not been elucidated. In the light of recent advancements in developing novel disease-specific therapies (e.g., myosin inhibitors and gene-based therapy), there is pressing need to gain a comprehensive understanding of the subclinical HCM and the transition to overt disease.
    We conducted a systematic review to summarize current knowledge about early phenotypic manifestations in humans with subclinical HCM who carry P/LP sarcomere gene variants in the absence of left ventricular hypertrophy (G+LVH−). We also sought to evaluate available information regarding the transition from subclinical to clinically overt disease, including factors which influence disease penetrance and expressivity.

    Methods

    The review was conducted to fulfill the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) criteria. Our review question was: “What is known about the subclinical HCM phenotype and about the transition from G+LVH− to overt HCM in humans?”. Any English-written original research published or pre-print manuscripts, meta-analyses, conference abstracts or case reports available online through electronic indexing on PubMed, Embase, Scopus, Web of Science, Google Scholar, Cochrane Library, MedRxiv, and BioRXiv providing insights about our review question were included in this study.
    A systematic search of the above academic search engines was used to identify relevant eligible publications up to 1st of March 2024. Search items were defined using the PECO (Patient/Exposure/Comparator/Outcomes) framework: (P)= (“hypertrophic cardiomyopathy”, “HCM”, “LV hypertrophy”); (E)= (“pre-phenotypic”, “prephenotypic”, “non-hypertrophic”, ”nonhypertrophic”, “pre-LVH”, “pre-clinical”, ”preclinical”, ”sub-clinical”, “subclinical”, “early disease”, “gene carrier”, “mutation carrier”, “gene positive”, “gene mutation”, “variant carrier”, “HCM carrier”); (C)= (“overt HCM”, “hypertrophic HCM”, “genotype positive HCM”, “phenotype positive HCM”); (O)= (“penetrance”, “phenotypic conversion”, “expressivity”, “age of onset”, “age of diagnosis”, “prevalence”, “manifestations”, “phenotype”, “morphological”, “structural”, “functional”, “dysfunction”, “characteristic”, “feature”, “transition to disease”, “disease progression”, “disease evolution”). We modified the search queries by including individual genes from Table 1 instead of using the generic term “gene”. We combined the categories of the PECO framework using “AND”, while grouping variations within each category were combined using “OR.” We excluded systematic and literature reviews; meta-analyses results were included. We also excluded studies which: (1) did not provide insights into subclinical HCM, (2) did not appraise the presence of variants using genotyping, (3) did not evaluate the presence of LVH with structural imaging (i.e., echocardiography or CMR), (4) were basic science studies such as human laboratory (e.g., cell cultures) or animal HCM studies, and (5) were conducted in syndromic HCM or HCM phenocopies. Despite the concordance between basic science models (e.g., mouse HCM models) and HCM in humans, not all insights derived from these studies are translational. Although excluded as part of the systematic search, selected insights of interest for future clinical trials about mechanisms and potential therapeutics from basic science studies were discussed in instances where human clinical data was lacking. Considering the absence of validated tools to assess study quality in the specific context of this review, we opted not to pursue a formal quality assessment. Nevertheless, we thoroughly critically appraised the included studies.

    Results

    Database searches identified 2326 articles. After screening the abstracts, 611 full text manuscripts were assessed. After applying our exclusion criteria, 91 were included in the qualitative analysis. Figure 1 presents the PRISMA flow chart.
    Morphologic abnormalities have been consistently identified in subclinical HCM, including larger atrial volumes9,10, bulky septomarginal trabeculum and increased septal convexity (Fig. 2A), higher prevalence of myocardial crypts11–13 (Fig. 2B), the presence of an LV apical-basal muscle bundle14, small LV cavity size3, higher maximal septal to lateral WT ratio10, increased LV apical rotation and twist15, multiple accessory papillary muscle heads and their anterior displacement16,17, elongated anterior mitral valve leaflets (MVL)16 (but normal posterior MVL18) (Fig. 2C) which can display systolic anterior motion19, and abnormal trabecula detected by CMR fractal analysis20 (Fig. 2D). MV abnormalities may represent a primary phenotype which evolves independently of LVH and increases susceptibility to developing LVOT obstruction18. Additionally, progression to overt HCM may be more likely in G+LVH− participants with longer MV leaflets7. Similarly, phenotypic conversion may be higher in those with greater, although normal, LV wall thickness at initial evaluation9.
    Abnormal myocardial energetics have been detected in subclinical HCM, but it is currently unclear whether this is related to insufficient energy generation and/or inefficient usage. For example, phosphorus-31 MR spectroscopy in subclinical HCM revealed a lower phosphocreatine-to-ATP ratio in the interventricular septum compared to other LV regions4. In addition, sarcomere variant carriers may also have a lower myocardial external efficiency (i.e., lower work per unit of oxygen consumption), with MYH7 potentially affected more than MYBPC3 carriers, even in the presence of normal myocardial blood flow21,22. This could be due to lower myocardial ATP levels (potentially secondary to the decoupling between the phosphocreatine kinase pathway and mitochondrial oxidative phosphorylation), altered myosin cycling rates23, and accelerated cross bridge detachment24. Currently, the impact of reduced myocardial energetics in the subclinical stage is poorly understood, and its link with disease progression remains elusive. Nonetheless, cardiac hypertrophy secondary to worsened myocardial energetics is known to occur in other genetic etiologies (e.g., mitochondrial ribonucleic acid25, AMP-activated protein kinase26 etc.).
    Focal myocardial fibrosis as identified by late gadolinium enhancement (LGE) on CMR imaging is present in ~60% of adults1 with overt HCM but its prevalence is lower (i.e., 40–50%) in the pediatric population27. It is thought to be related to disease duration and has been associated with the extent of hypertrophy28, inducible ischemia29, sudden death risk30, LV dilation, and systolic dysfunction31. Indeed, focal LGE is very rarely seen in the subclinical stage6,27. Nonetheless, animal models of HCM have demonstrated that profibrotic pathways are upregulated before development of histological fibrosis and hypertrophy32. Focused human studies have suggested that a profibrotic state may be present in G+LVH− individuals. Increased serum levels of C-terminal pro-peptide of type I procollagen [PICP] and PICP-to-C-terminal telopeptide of type I collagen ratios5 (indicating more collagen synthesis than degradation leading to extracellular matrix [ECM] deposition) have been detected. Moreover, a six-peptide multiplex biomarker panel consisting mostly of ECM-related proteins was found to be elevated in overt HCM and G+LVH− compared to healthy controls33. Additionally, in contrast to focal fibrosis, CMR studies in G+LVH− demonstrated that interstitial fibrosis may be increased. There is a longer native myocardial T134,35 (Fig. 2E) and higher extracellular volume (ECV)6 (Fig. 2G) using myocardial mapping sequences. ECV also correlated with higher serum N-terminal pro-peptide of B-type natriuretic peptide (NT-proBNP) levels and lower e’ velocity on echocardiography, suggesting that increased ECV has physiologic relevance and leads to increased hemodynamic stress and diastolic abnormalities6. Thus, it has been speculated that a predisposition for developing myocardial fibrosis may be an early direct consequence of pathogenic sarcomere variants, not exclusively secondary to LVH36,37. The absence or minimal presence of LGE in subclinical (Fig. 2H) may be a result of the limitations of using LGE to detect fibrosis (e.g., need to null against healthy myocardium) rather than signifying the absence of fibrosis or fibrotic tendencies.
    From a treatment perspective, activation of transforming growth factor β (TGF-β) is thought to be one of the mediators of profibrotic processes in HCM36. Inhibition of these pathways may provide an opportunity to alter the genotype-phenotype transition in variant carriers. The renin-angiotensin-aldosterone system may be involved in the fibrotic remodeling as angiotensin II upregulates TGF-β38. In animal models, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone antagonists were shown to reduce the development of hypertrophy and fibrosis39–41. Translation to HCM in humans was investigated in the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial42. Valsartan appeared to improve cardiac structure and function in early-stage but clinically overt sarcomere-related HCM, however significant benefit could not be detected in a small exploratory cohort of gene variant carriers with subclinical HCM9.
    ECV expansion might explain some of the ECG abnormalities such as the presence of Q-waves, higher RS voltages sometimes meeting ECG LVH criteria (e.g., Sokolow-Lyon), and ST segment/T-wave changes identified in subclinical HCM (Fig. 3)43. However, these ECG findings are non-specific as they can exist in health in certain ethnicities (e.g., African-Caribbeans) or in athletes, but can also be present in other conditions (e.g., hypertension). However, an abnormal ECG was associated with a 4-fold higher risk of developing overt HCM over 15 years in a longitudinal study44.
    Tissue Doppler echocardiography has identified impaired relaxation, as reflected by the lower mitral annular velocities (e’), and increased filling pressures, reflected by increased E/e’ ratio, in subclinical HCM45–47. Additionally, G+/LVH- individuals with lower global e’ velocities7 appeared to be more likely to progress to overt HCM.
    Besides LV stiffening secondary to ECV expansion6, additional proposed pathophysiological mechanisms underlying diastolic dysfunction in subclinical HCM include increased cytosolic Ca2+ 48, increased myofilament Ca2+ sensitivity due to reduced troponin phosphorylation49–51, smaller LV cavity size3, and altered myocardial activation as a direct result of the sarcomere variant (e.g., altered actin ATPase activity52,53, reduced super-relaxed state of myosin54,55, higher gliding velocity52,56, and greater force generation52,57). Importantly, mavacamten (a myosin ATPase inhibitor) was able to suppress the development of LVH, myocardial disarray, and fibrosis in G+LVH− animal models58. However, the role of myosin ATPase inhibitors in human sarcomere variant carriers has not been explored in clinical trials.
    Although LV ejection fraction is usually supranormal59,60, sarcomere variant carriers have been shown to have impaired myocardial dynamics characterized by worse strain values suggesting some impairment of systolic function10,61–63. G+LVH− individuals with higher NT-proBNP may be more likely to develop overt HCM64.
    Increased cytosolic Ca2+ has been shown to precede the development of LVH in some animal models of HCM48. Since Ca2+ is an inotrope, the increased Ca2+ signaling might also underlie supranormal systolic function59,60 identified in subclinical HCM by CMR. Following beneficial results seen in a mouse model of HCM, diltiazem65, a calcium-channel blocker, increased LV end diastolic diameter and reduced wall thickness in G+/LVH– in a pilot human clinical trial, suggesting a potential disease-modifying role for calcium-channel blockers if used at the subclinical HCM stage3.
    Increased cytosolic Ca2+ may potentially lead to over-activation of calmodulin kinase, thus disinhibiting the growth factor, mammalian target of rapamycin (mTOR) and facilitating development of LVH. Indeed, mTOR inhibitors66–69 were able to attenuate LVH development in G+LVH− animal models. However, clinical translation of mTOR inhibitors has not yet been investigated in humans.
    Microvascular dysfunction is also linked to abnormal morphology and diastolic dysfunction. On a background of dysfunctional angiogenesis, even a small degree of impaired relaxation may compress the microvasculature and further reduce the capillary MBF and increase susceptibility to ischemia70. Regionally and globally impaired myocardial perfusion on adenosine stress perfusion CMR was observed in G+LVH− individuals, suggesting microvascular dysfunction (Fig. 2F)8. Moreover, oxygen-sensitive CMR sequences suggested that subclinical HCM is characterized by impaired tissue oxygenation71. In response to reduced MBF, the cardiomyocytes may express hypoxia inducible factors (HIFs) which could trigger a signaling cascade translating into cardiomyocyte hypertrophy and fibroblast proliferation. A small study in pediatric HCM suggested that HIF1A upregulation was associated with a younger age of HCM onset, increased LVH and worsened diastolic dysfunction72. In addition, basic science studies suggest that P/LP MYBPC3 and MYH7 variants may induce HIF signaling early in the disease pathogenesis73.

    Discussion

    This review summarizes subtle early phenotypic manifestations that can be identified in sarcomere variant carriers before a diagnosis of HCM can be established, when LV wall thickness is normal. Thematic groups can be established, for example, both myocardial and MV morphological abnormalities have been reported in subclinical HCM, including smaller LV cavity size3, increased septal convexity, and longer MV leaflets16. Sarcomere variants may lead to the pathological activation of pro-fibrotic pathways36,37. Indeed, increased interstitial fibrosis has been detected in G+LVH− individuals6 and may partly underlie the impaired relaxation and ECG abnormalities seen in the subclinical stage. Notably, ECV decreases in athletes, suggesting that physiological hypertrophy occurs without ECM expansion74. Inefficient myocardial energetics in the subclinical state4,21,22 has been postulated to contribute to “compensatory” hypertrophy, although robust supporting evidence is lacking. However, despite identifying early phenotypic manifestations, to date, a unifying theory has not been established to explain how sarcomere variants lead to HCM. To establish the sequence of events, a more comprehensive understanding of the pathways activated in the earliest stages of disease is needed. To map the changes which occur as sarcomere variant carriers transition to overt disease, a multidisciplinary approach integrating basic science and long-term prospective clinical studies is vital. This approach will hopefully also identify therapeutic targets that can alter the natural history of the disease, leading to the development of novel disease-modifying strategies that will slow progression or prevent the emergence of HCM.
    The transition from subclinical to clinically overt HCM is poorly captured and poorly understood. Because of this uncertainty, surveillance of at-risk relatives is currently relatively crude with lifelong clinical screening uniformly recommended, starting with first degree relatives,75 76 although penetrance is incomplete and risk for disease development is not equally distributed.
    Previous studies have identified the affected gene2 (variants in MYBPC377,78, MYH779,80, TTNT281,82 and TNNI383,84), co-existence of multiple P/LP variants85, a positive family history2, older age86, male sex87, ethnicity88, higher body size89, higher blood pressure90, and an abnormal ECG44 as risk factors for developing penetrant disease in the short term, however it remains unclear how these factors influence the subclinical phenotype or the pathophysiological mechanisms driving the transition from subclinical to clinically overt disease. Another study suggested that progression to HCM was more likely in G+LVH− with longer MV leaflets, lower global E’ velocities on Doppler echocardiography and higher serum NT-proBNP over a median follow-up of 3 years starting from a mean age of 16 years7. Additionally, individuals relatively greater but still normal septal thickness and larger left atrial volume (indexed to body surface area) at baseline may also be more likely to develop overt HCM during a 2-year longitudinal follow-up starting from a mean age of 16 years9. If none of these features are present, a longer interval between screenings may be reasonable. Conversely, if these features or other early phenotypic manifestations are identified, more frequent surveillance would be appropriate. Further study is needed to determine how to better tailor and individualize long term family screening.
    Recognizing that the phenotype of HCM extends beyond just increased LV wall thickness is important to improve diagnosis and understanding of this complex cardiomyopathy. However, diagnostic criteria for HCM have remained unaltered for >50 years and focus only on a dichotomous threshold of maximal LV wall thickness: >15mm in probands and >13mm in sarcomere variant carriers or relatives of probands given the higher pretest probability of HCM75,76. LV wall thickness is influenced by age, sex, ethnicity, body size, physical fitness, and the presence of co-morbidities (e.g., pressure overload)91. Accounting for demographic characteristics and comorbidities will allow us to develop more personalized and biologically relevant thresholds to define pathologic LVH. In addition to considering the totality of phenotypic manifestations, using more accurate thresholds for LVH will improve the diagnosis HCM.

    Conclusions

    The absence of LVH is not equivalent with the absence of a phenotype in sarcomere variant carriers. Individuals with subclinical HCM can have abnormal cardiac morphology, pro-fibrotic remodeling, myocardial tissue abnormalities, impaired relaxation, abnormal Ca2+ signaling, microvascular dysfunction and altered myocardial energetics. The subclinical phase of HCM provides a unique window of opportunity to interrupt disease progression, as disease modification may be more biologically feasible earlier, before cardiac remodeling is advanced, and pathophysiology entrenched. To leverage this opportunity, large-scale longitudinal studies of G+LVH− individuals are critically needed to understand disease trajectories, to identify robust, dynamic biomarkers that track disease progression or incipient transition to overt HCM, and to discover critical periods, where phenotypic progression may be intercepted. Such knowledge will also have immediate clinical impact by informing family management. Accurate stratification of risk for developing clinical HCM would reduce and appropriately focus the burden of longitudinal screening. These insights will also guide the development of disease-modifying therapies intended to prevent HCM in genetically susceptible individuals.
    CTDr. Constantin-Cristian Topriceanu

    Dr. Constantin-Cristian Topriceanu

    Cardiology · Advanced Cardiac Imaging
    Mayo Clinic
    constantincristian